Prize strap
The company has not yet announced the price band for its IPO. Investors can place bids in lots, with the party size details that must be updated closer to the opening date.
Problem structure
The IPO consists of a new issue of 1 crore stock shares. Up to 50% of the net problem will be reserved for qualified institutional buyers (QIBs), at least 35% for retail investors and at least 15% for non-institutional investors (NIIS).
Company background
Amanta Healthcare, included in 1994, is involved in the development, production and marketing of sterile liquid formulations and medical devices. The product portfolio comprises IV, fluids, dilution resources, ophthalmic solutions, breathing care products, irrigation solutions and eye liters. The company uses advanced aseptic blow-fill-seal (ABFS) and injection stretch bladder formation (ISBM) technologies for packaging.
Amanta Markets More than 45 generic products via 320 distributors in India and export to 21 countries in Africa, Latin -America, the UK and other regions.
Financial performance
For FY25, Amanta Healthcare reported sales of RS 276.09 Crore, slightly lower than RS 281.61 Crore in FY24. However, the profit after tax rose by 189% to RS 10.5 Crore in FY25, compared to RS 3.63 Crore in the previous year.
Objects of the IPO
The IPO yield will be used for capital expenditure, including RS 70 Crore for setting up a new steriport production line at Hararyala and RS 30.13 Crore for another new line for SVP at the same location. The balance will be used for general business purposes.
Beine Capital Advisors is the lead manager of the book, while MUFG Intime India is the registrar of the issue.
(Disclaimer: recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)
#Amanta #Healthcare #announces #IPO #dates